We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42–70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II–IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10–42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23–65) at 3 years. The median follow-up period was 39 (range 14–60) months. Overall survival was 69% (95% CI, 50–83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience / Memoli, M.; Paviglianiti, A.; Malard, F.; Battipaglia, G.; Brissot, E.; Mediavilla, C.; Bianchessi, A.; Banet, A.; Van de Wyngaert, Z.; Ledraa, T.; Belhocine, R.; Sestili, S.; Lapusan, S.; Hirsch, P.; Favale, F.; Boussaroque, A.; Bonnin, A.; Vekhoff, A.; Legrand, O.; Mohty, M.; Dulery, R.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 62:2(2021), pp. 419-427. [10.1080/10428194.2020.1827246]
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience
Memoli M.;Battipaglia G.;
2021
Abstract
We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42–70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II–IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10–42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23–65) at 3 years. The median follow-up period was 39 (range 14–60) months. Overall survival was 69% (95% CI, 50–83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
